Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 10/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.41 |
| ▸ | SOAT1 | P35610 | 3/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | ACSL1 | P33121 | 1/20 | 0.40 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10185244 | 0.90 | DGAT1 (0.50) | DGAT1KMT2ASOAT1 | |
| SCHEMBL10186130 | 0.90 | DGAT1 (0.50) | DGAT1KMT2ASOAT1 | |
| SCHEMBL10186404 | 0.85 | DGAT1 (0.53) | DGAT1SOAT1 | |
| SCHEMBL10184453 | 0.84 | CHRM4 (0.57) | DGAT1HSD17B10CHRM4ACSL1 | |
| SCHEMBL10186137 | 0.84 | DGAT1 (0.52) | DGAT1KMT2A | |
| SCHEMBL10184397 | 0.84 | LPAR1 (0.48) | DGAT1KMT2AHSD17B10SOAT1 | |
| SCHEMBL10184403 | 0.84 | DGAT1 (0.54) | DGAT1KMT2AHSD17B10 | |
| SCHEMBL10184513 | 0.83 | DGAT1 (0.49) | DGAT1KMT2AHSD17B10F10 | |
| SCHEMBL10186201 | 0.83 | DGAT1 (0.55) | DGAT1KMT2ASOAT1 | |
| SCHEMBL10185255 | 0.83 | NPC1 (0.47) | DGAT1KMT2AF10SOAT1SLC5A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-2010122968-A1 | DIACYLETHYLENEDIAMINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | DGAT1 1/4885KMT2A 441/4885HSD17B10 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.